News | September 23, 2024
DevCo completes strategic capital raise for investment in Medix Biochemica
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
The raised capital enables Medix Biochemica to continue execution of inorganic growth initiatives
The exclusive hospital will help address health complexities concerning women and children, specializing in high-end obstetrics, comprehensive gynecological, neonatal & pediatric care
Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
The grant is designated for the research and development of Pyronaridine
This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,
India Business grew by 11.9% YoY to Rs. 1196.2 crore
Subscribe To Our Newsletter & Stay Updated
